Breaking News:
About Oligomerix
Oligomerix, Inc., is a privately held clinical stage biotechnology company pioneering the development of disease-modifying, oral small molecule therapeutics targeting protein aggregation in Alzheimer’s disease and rare neurodegenerative diseases such as progressive supranuclear palsy (PSP).
Technology
Oligomerix’s lead candidate is a small molecule inhibitor of tau self-association that targets the beginning of the tau aggregation cascade and its progression.
Pipeline
Oligomerix’s platform includes our lead compound (OLX07010) and 2nd generation series of compounds.
News
August 9, 2022
July 20, 2022
